<DOC>
	<DOCNO>NCT02888730</DOCNO>
	<brief_summary>Patients cystic fibrosis frequently develop chronic rhinosinusitis . Bacterial colonization facilitate reduced mucociliary function previous study suggest microbiology upper airway might influence microbiology low airway . The aim randomize control study demonstrate efficacy antibiotic deliver nebulized sonic aerosol therapy decrease bacterial load sinuses medium ostia improve sino-nasal symptom endoscopic score , quality life lung function</brief_summary>
	<brief_title>Tobramycin Delivered Nebulized Sonic Aerosol Chronic Rhinosinusitis Treatment Cystic Fibrosis Patients</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) common lethal autosomal recessive disorder Caucasian population affect ~1:3000 child , carrier frequency 1:25 . It multisystem disorder pulmonary sinonasal involvement occur 90-100 % patient , 86 % child nasal polyp . Patients CF develop chronic rhinosinusitis ( CRS ) due defect cystic fibrosis Transmembrane Regulator ( CFTR ) protein . The membrane line paranasal sinus nose identical membrane lining lung . As low airway ( LAW ) defect CFTR protein result viscous mucus . Consequently mucociliary function reduce , facilitate bacterial colonization eventually infection lead rhinosinusitis . In past decade infection low airway prominent focus treatment protocols CF . Over year infection upper airway ( UAW ) gradually gain attention CF . Previous research microbiology upper airway ( UAW ) CF display Haemophilus influenzae , Pseudomonas aeruginosa Staphylococcus aureus frequently culture UAW . Since several study show concordance organism UAW LAW CF , hypothesis evolve UAW might influence patient pulmonary status . Moreover , comparison UAW LAW culture CF adult patient show Pseudomonas aeruginosa culture UAW eradication therapy may suggest persistence Pseudomonas aeruginosa UAW . This problem highlight double lung transplant UAW also appear protective niche adapt clone bacteria , intermittently spread pathogen lung . CRS treatment CF patient base daily nasal lavages local systemic antibiotic treatment eradicate bacteria sinus . Local therapy favour CRS treatment CF patient avoid antibiotic side effect , change organism resistance pattern . Sonic aerosol therapy antibiotic 15 day commonly use CRS non CF patient improve sinonasal symptom reduce purulent secretion sound addition pneumatic aerosol head corpse 's model create acoustic pressure ostia improve aerosol penetration maxillary sinus . However efficacy bacterial carrying sinus prove . At opposite , efficacy aerosol tobramycin LAW prove CF patient decrease density Pseudomonas aeruginosa , improvement FEV , few pulmonary exacerbation . At present time , efficacy antibiotic ( tobramycin ) deliver nebulized sonic aerosol CRS treatment CF patient unknown particularly bacterial carrying . The aim study demonstrate nebulized sonic aerosol therapy tobramycin Cystic Fibrosis patient decrease significantly bacterial carry sinus , sinus ostia middle meatus sputum compare nebulized sonic aerosol therapy placebo nebulized sonic aerosol therapy improve sino-nasal symptom endoscopic score , quality life lung function .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Patients older 7 year follow 6 CRCM center ( Cr√©teil , Marseille , Nantes , Toulouse , ClermontFerrand Nice ) . We choose enroll child age 7 year well adherence nebulization treatment young child . Diagnosis cystic fibrosis confirm sweat test ( &gt; 60mmol/L ) and/or identification two CFcausing mutation Confirmed chronic rhinosinusitis Ear Nose Throat doctor endoscopic examination : bilateral mucopurulent secretion middle meatus present long 12 week without nasal polyp Positive bacteria susceptibility tobramycin sample middle meatus Susceptibility bacteria tobramycin confirm Pulmonary examination enrollment Written inform consent obtain enrollment patient ( consent minor 's parent child ) Social security affiliation Oral antibiotic therapy one month enrollment enrollment another protocol antibiotic Ongoing aerosolize tobramycin endobronchial infection avoid overlap treatment lung treatment sinusitis Abnormal auditory acuity ( decrease 20dB auditory acuity ) Hypersensibility allergenecity aminoglycosides FEV &lt; 25 % FVC 40 % value predict height Transplant patient patient transplant list Patient nasal oxygen noninvasive ventilation Pregnant woman Breastfeeding No Social security affiliation Informed consent non obtain enrollment patient ( consent minor 's parent child )</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>chronic rhinosinusitis</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>tobramycin</keyword>
	<keyword>nebulized sonic aerosol therapy</keyword>
</DOC>